News Channels

25 Jul 2017 Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
25 Jul 2017 Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody
25 Jul 2017 Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
25 Jul 2017 Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia
25 Jul 2017 Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
25 Jul 2017 Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN
25 Jul 2017 The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE
25 Jul 2017 Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration
25 Jul 2017 NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
25 Jul 2017 Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen
25 Jul 2017 Takeda and BioSurfaces Announce Joint Research Program to Explore Promising Devices to Treat Gastrointestinal Diseases
25 Jul 2017 ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
25 Jul 2017 Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
25 Jul 2017 Lilly and Incyte Provide Update on Baricitinib
25 Jul 2017 Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
25 Jul 2017 BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
25 Jul 2017 U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications
25 Jul 2017 Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
25 Jul 2017 UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
25 Jul 2017 Eisai submits simultaneous applications in the United States and Europe for lenvatinib in hepatocellular carcinoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top